SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in response to Ms. Wojcicki's previously disclosed preliminary non-binding indication of interest to acquire all of the outstanding shares of 23andMe not owned by her or her ...

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in response to Ms. Wojcicki's previously disclosed preliminary non-binding indication of interest to acquire all of the outstanding shares of 23andMe not owned by her or her ...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, has received a preliminary nonbinding indication of interest from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per sha ...

A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024. Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1. Wojcicki said she was prepared to acquire all of 23andMe's outstanding shares of common stock in cash for 40 cents per share, according to a Wednesday filing with the U.S. Securities and Exchange Commission. She expressed interest in acquiring the company in April, s ...

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s ...

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's ...

SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies h ...

SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection, risk reduction, and care. While recent developments in tumor genetic testing and targeted therapies ...

文章核心观点 - 23andMe与Nightingale Health建立战略合作,将Nightingale Health的血液生物标志物检测技术引入23andMe的会员服务 [1][2][3][4][5][6][7] - 这项合作将为23andMe会员提供免费的血液检测服务,帮助他们更好地了解自身健康状况,采取预防性措施 [5][6][7] - 双方希望通过整合各自的技术,为客户提供更全面的健康评估和持续的健康管理服务 [6][7] 公司信息 - 23andMe是一家以遗传学为基础的消费者健康和治疗公司,致力于为消费者提供更健康的未来 [7] - Nightingale Health是一家生物标志物检测和风险预测的先驱公司 [1][2][7] 合作内容 - 23andMe将为最多5,000名会员提供Nightingale Health的远程健康检查服务,无需付费 [5] - 这项试点旨在评估客户对血液检测、居家样本采集以及将这些数据与23andMe现有的个人遗传产品相结合的反馈 [5] 合作目标 - 帮助个人识别健康风险,通过主动检测、治疗、指导和行为改变来预防疾病 [6][7] - 结合双方的技术,为客户提供更全面的健康评估和持续的健康管理服务 [6][7]

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, includi ...